The full-length IgG format also enables further modification of the Fc region for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) or to prevent binding to Fc-γ receptors on immune ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Trastuzumab captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

PEG modification, IL-2 mutant design, fusion Fc, bispecific antibody design, combination immunization checkpoint antibody medication treatment, and other tactics have all been used by biopharma ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the anti-A proliferation-inducing ligand (APRIL) monoclonal antibody, CLYM116 ...

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically ...

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized ...

(A) The structure of a monoclonal antibody, such as infliximab, adalimumab or golimumab, and (B) the structure of certolizumab. Fab: Antibody-binding fragment of immunoglobulin; Fc: Constant fragment.